SPRB insider transaction filings
SPRUCE BIOSCIENCES, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-29. Screen SPRB transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Quartel Adrian W — Chief Medical Officer | 1 | — | — | 1 |
| Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | 1 | — | — | 1 |
Recent Form 4 filings — SPRUCE BIOSCIENCES, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-29 | 4 | Quartel Adrian W — Chief Medical Officer | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-07-09 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 266 @ $4.53 | EDGAR |
| 2026-05-26 | 4 | Walbert Keli — Director | Grant/award (A): 1,700 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Barretto-Ko Percival — Director | Grant/award (A): 1,700 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 1,700 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | GREY MICHAEL G — Executive Chairman, Director | Grant/award (A): 1,700 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 1,700 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Hooks Corwin Dale — Chief Commercial Officer | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Ways Douglas Kirk — Interim Chief Medical Officer, Director | Option exercise (M): 1,250 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 · Option exercise (M): 1,250 (derivative) @ $0 · Grant/award (A): 266 (derivative) · Disposition to issuer (D): 266 (derivative) · Grant/award (A): 400 (derivative) · +1 more | EDGAR |
| 2026-01-05 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 4,690 @ $4.53 | EDGAR |
| 2025-12-17 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 1,480 @ $0 · Tax withholding (F): 752 @ $80.67 · Option exercise (M): 1,196 @ $0 · Tax withholding (F): 608 @ $80.67 · Grant/award (A): 1,666 (derivative) · Disposition to issuer (D): 1,666 (derivative) · +2 more | EDGAR |
| 2025-12-17 | 4 | Gharib Samir M. — PRESIDENT AND CFO | Option exercise (M): 496 @ $0 · Tax withholding (F): 178 @ $80.67 · Option exercise (M): 513 @ $0 · Tax withholding (F): 184 @ $80.67 · Option exercise (M): 496 (derivative) @ $0 · Option exercise (M): 513 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Walbert Keli — Director | Grant/award (A): 3,400 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Barretto-Ko Percival — Director | Grant/award (A): 800 (derivative) · Disposition to issuer (D): 800 (derivative) | EDGAR |
| 2025-12-15 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2025-12-15 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 173 (derivative) · Disposition to issuer (D): 173 (derivative) · Grant/award (A): 309 (derivative) · Disposition to issuer (D): 309 (derivative) · Grant/award (A): 362 (derivative) · Disposition to issuer (D): 362 (derivative) · +4 more | EDGAR |
| 2025-12-15 | 4 | Gharib Samir M. — PRESIDENT AND CFO | Grant/award (A): 1,579 (derivative) · Disposition to issuer (D): 1,579 (derivative) · Grant/award (A): 953 (derivative) · Disposition to issuer (D): 953 (derivative) · Grant/award (A): 733 (derivative) · Disposition to issuer (D): 733 (derivative) · +4 more | EDGAR |
| 2025-12-15 | 4 | GREY MICHAEL G — Executive Chairman, Director | Grant/award (A): 387 (derivative) · Disposition to issuer (D): 387 (derivative) · Grant/award (A): 1,255 (derivative) · Disposition to issuer (D): 1,255 (derivative) · Grant/award (A): 1,499 (derivative) · Disposition to issuer (D): 1,499 (derivative) · +6 more | EDGAR |
| 2025-12-15 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 458 (derivative) · Disposition to issuer (D): 458 (derivative) · Grant/award (A): 88 (derivative) · Disposition to issuer (D): 88 (derivative) · Grant/award (A): 400 (derivative) · Disposition to issuer (D): 400 (derivative) | EDGAR |
| 2025-12-12 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 1,196 @ $0 · Tax withholding (F): 428 @ $85.67 · Option exercise (M): 4,950 @ $0 · Tax withholding (F): 2,194 @ $88.41 · Option exercise (M): 1,196 (derivative) @ $0 · Grant/award (A): 19,800 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-12 | 4 | Gharib Samir M. — PRESIDENT AND CFO | Option exercise (M): 514 @ $0 · Tax withholding (F): 184 @ $85.67 · Option exercise (M): 1,900 @ $0 · Tax withholding (F): 680 @ $88.41 · Option exercise (M): 514 (derivative) @ $0 · Grant/award (A): 7,600 (derivative) @ $0 · +1 more | EDGAR |
| 2025-10-22 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 4,784 @ $0 · Tax withholding (F): 1,539 @ $148.16 · Grant/award (A): 4,784 (derivative) @ $0 · Option exercise (M): 4,784 (derivative) @ $0 | EDGAR |
| 2025-10-22 | 4 | Gharib Samir M. — PRESIDENT AND CFO | Option exercise (M): 2,053 @ $0 · Tax withholding (F): 661 @ $148.16 · Grant/award (A): 2,053 (derivative) @ $0 · Option exercise (M): 2,053 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Parkman Healthcare Partners LLC — 10% owner Martinez Gregory — 10% owner | Purchase (P): 256 @ $17.91 · Sale (S): 232 @ $19.33 · Sale (S): 25 @ $17.46 | EDGAR |
| 2025-10-08 | 4 | Parkman Healthcare Partners LLC — 10% owner | Purchase (P): 256 @ $17.91 · Sale (S): 232 @ $19.33 · Sale (S): 25 @ $17.46 | EDGAR |
| 2025-07-24 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Barretto-Ko Percival — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Ways Kirk — Interim Chief Medical Officer, Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Muralidhar Bali — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Aynechi Tiba — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | GREY MICHAEL G — Executive Chairman, Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-12-20 | 4 | Charlton Ralph William III — CHIEF MEDICAL OFFICER | Option exercise (M): 106,400 @ $0 · Tax withholding (F): 37,964 @ $0.54 · Option exercise (M): 26,600 @ $0 · Tax withholding (F): 9,491 @ $0.39 · Option exercise (M): 31,750 @ $0 · Tax withholding (F): 11,329 @ $0.39 · +3 more | EDGAR |
| 2024-12-20 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 358,800 @ $0 · Tax withholding (F): 128,020 @ $0.54 · Option exercise (M): 89,700 @ $0 · Tax withholding (F): 32,005 @ $0.39 · Option exercise (M): 111,000 @ $0 · Tax withholding (F): 39,605 @ $0.39 · +3 more | EDGAR |
| 2024-12-20 | 4 | Gharib Samir M. — PRESIDENT AND CFO | Option exercise (M): 154,000 @ $0 · Tax withholding (F): 54,948 @ $0.54 · Option exercise (M): 38,500 @ $0 · Tax withholding (F): 13,737 @ $0.39 · Option exercise (M): 37,250 @ $0 · Tax withholding (F): 13,291 @ $0.39 · +3 more | EDGAR |
| 2024-05-24 | 4 | Ways Kirk — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | SIMPSON CAMILLA V — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Muralidhar Bali — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Barretto-Ko Percival — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Aynechi Tiba — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | GREY MICHAEL G — Executive Chairman, Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 465,021 @ $0.75 | EDGAR |
| 2024-03-20 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 842,020 @ $0.77 · Sale (S): 593,000 @ $0.76 · Sale (S): 359,979 @ $0.73 | EDGAR |
| 2024-03-18 | 4 | Charlton Ralph William III — CHIEF MEDICAL OFFICER | Grant/award (A): 106,400 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Szwarcberg Javier B. — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 358,800 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Gharib Samir M. — PRESIDENT AND CFO | Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 1,912,316 @ $0.89 | EDGAR |
| 2024-01-03 | 4 | Charlton Ralph William III — Chief Medical Officer | Grant/award (A): 9,361 @ $0.98 | EDGAR |
| 2024-01-03 | 4 | Gharib Samir M. — President & CFO | Grant/award (A): 11,255 @ $0.98 | EDGAR |
Recent 8-K events — SPRUCE BIOSCIENCES, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-03-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SPRB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →